Not applicableUnknownNCT05598684
What this trial is testing
SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases
Who this might be right for
Crohn DiseaseUlcerative ColitisRheumatoid Arthritis+2 more
Fresenius Kabi, France 600